期刊
LEUKEMIA
卷 24, 期 4, 页码 806-812出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2010.2
关键词
acute lymphoblastic leukemia; t(4;11) translocation; nuclear factor kappa B (NF-kappa B); interferon beta (IFN beta)
资金
- Assisi Foundation of Memphis
- National Cancer Institute [R01CA1333222-01A1, CA21766]
- University of Tennessee Health Science Center
- American Lebanese Syrian Associated Charities
- NATIONAL CANCER INSTITUTE [R01CA133322] Funding Source: NIH RePORTER
Acute lymphoblastic leukemia (ALL) harboring the t(4;11) translocation is associated with a very poor prognosis; innovative treatment strategies are required to improve the current 5-year survival rate of 30-40%. Interferon beta (IFN beta) has shown promise in the treatment of both solid and hematologic malignancies, although the short half-life and toxicity associated with high doses have limited its clinical utility. To overcome these limitations, we investigated the effect of continuous, gene transfer-mediated delivery of IFN beta using adeno-associated virus (AAV)-mediated expression, on ALL cells with the t(4; 11) translocation. We found that this method of IFN beta delivery resulted in complete remission of leukemia in a murine model. However, leukemic cells eventually became resistant to IFN beta and relapse was observed. Activation of NF-kappa B was identified as a mechanism for IFN beta resistance, and inhibition of NF-kappa B activity in resistant cells sensitized cells to IFN beta. IFN beta combined with agents that inhibit NF-kappa B could have therapeutic potential in the treatment of children with mixed lineage leukemia subtype ALL. Leukemia (2010) 24, 806-812; doi: 10.1038/leu.2010.2; published online 4 February 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据